Legend's Pipeline Is Starting To Matter

Legend Biotech is transitioning from a capital-intensive biotech to a profitable, CARVYKTI-driven commercial cell therapy company. Q2 results highlight 52% YoY revenue growth, strong international CARVYKTI momentum, and a swing to $57.7M operating income, signaling sustainable profitability. CARVYKTI's 50% YoY sales growth is driven by earlier-line adoption and global expansion, with over 70% use now in 2L–4L settings.